Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know
Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know
来自Calliditas Therapeutics分析师评级的关键见解：你需要知道的
In the last three months, 5 analysts have published ratings on Calliditas Therapeutics (NASDAQ:CALT), offering a diverse range of perspectives from bullish to bearish.
在过去的三个月中，有5位分析师公布了对Calliditas Therapeutics（纳斯达克股票代码：CALT）的评级，提供了从看涨到看跌的不同视角。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.4, along with a high estimate of $45.00 and a low estimate of $39.00. Highlighting a 25.64% decrease, the current average has fallen from the previous average price target of $54.33.
分析师提供了更深入的见解，确定了12个月的目标股价，平均目标价为40.4美元，最高估计为45.00美元，低估值为39.00美元。当前的平均价格已从之前的平均目标价54.33美元有所下降，这凸显了25.64％的跌幅。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析师评级：详细明细
A clear picture of...
通过对分...
登录免费看全文
登录/注册